Circle Pharma key facts
as of Oct 2026- Developer of a new generation of macrocycle therapies designed for cell-permeable delivery and can be delivered by multiple routes, including oral administration.
- Circle Pharma is valued at approximately $269.0M as of Oct 2026, set at its later-stage round, Jan 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $212.1M across 4 recorded rounds; the latest was Later Stage VC ($92.4M) in Jun 2024.
- Notable investors include Hemisphere Ventures, CSC UpShot Ventures, Mission BioCapital, Pfizer Ventures, Euclidean Capital — 23 tracked in total.
- Circle Pharma has filed 7 Form Ds with the SEC since 2016, most recently Jan 2025 ($92.4M sold to 14 investors).
- Status: Privately Held (backing).
Valued at $269.0M at its later-stage round, Jan 2025. Nothing has traded since.
- ·The complete investor list: 23 names
- ·Watch Circle Pharma: the Monday email on marks, rounds and moves
Circle Pharma funding rounds
4 roundsWho backs Circle Pharma
23+Circle Pharma valuation
Circle Pharma was valued at $269 million at its later-stage round in Jan 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Circle Pharma raised?
Circle Pharma has raised $212 million across 4 recorded rounds since 2016. The largest was a $92.4 million later-stage round in Jun 2024.
Circle Pharma has filed 7 Form Ds with the SEC since 2016, most recently in Jan 2025 ($92.4 million sold to 14 investors).
Circle Pharma investors
23 investors are on record for Circle Pharma, including Hemisphere Ventures, CSC UpShot Ventures, Mission BioCapital and Pfizer Ventures. By type, the record holds 5 venture capital firms and 1 family office. The later-stage round in Jun 2024 drew 14 investors.
About Circle Pharma
Developer of a new generation of macrocycle therapies designed for cell-permeable delivery and can be delivered by multiple routes, including oral administration. The company's platform combines structure-based rational drug design and advanced synthetic chemistry to develop first-in-class macrocycle therapeutics for challenging targets to address unmet clinical needs, enabling doctors to focus on internal development efforts on intracellular protein-protein interactions that are key drivers in cancer.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2012
- Employees
- 56
- Website
- circlepharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.